A Phase II Study of BTK Inhibitor Acalabrutinib and PI3Kδ Inhibitor Umbralisib in Combination With Ublituximab (AU2) in Patients With Previously Untreated Mantle Cell Lymphoma (MCL)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Nov 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Acalabrutinib (Primary) ; Ublituximab (Primary) ; Umbralisib (Primary)
Indications Mantle-cell lymphoma
Focus Therapeutic Use

15 Nov 2023 Planned End Date changed from 20 Sep 2023 to 20 Sep 2025.
28 Feb 2023 Status changed from suspended to active, no longer recruiting.
13 Dec 2022 Results (n=12) assessing the safety and efficacy of umbralisib and ublituximab in patients with previously untreated mantle cell lymphoma, presented at the 64th American Society of Hematology Annual Meeting and Exposition.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com